LTR Pharma is a public company, with operations based in Brisbane, Australia. Our focus is on holistically improving men’s health, physically and mentally, through the commercialisation of an innovative intranasal spray treatment for Erectile Dysfunction (ED).

ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets.

Our lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work in 10 minutes or less.

LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.

About LTR Pharma

  • LTR Pharma is a clinical stage pharmaceutical company
  • SPONTAN® (SDS-089) is a first in class intranasal drug (PDE5) delivery platform for ED
  • Expected fast track FDA approval – targeting US NDA Filing within two years
  • Rapid onset of action is a key differentiator to existing ED products
  • Lower dose provides less systematic exposure and reduced side effects
  • Targeting significant unmet clinical needs in large market

Receive our latest news and investor updates​

By entering your email address you are agreeing to our privacy policy.